Today is a special day for Relay Therapeutics. The FDA has approved lirafugratinib (brand name LYRFIGTU™) for patients with FGFR2-driven #cholangiocarcinoma, brought to patients by our commercial partner Elevar Therapeutics following our global out-licensing agreement in 2024. This is the first medicine to emerge from our Dynamo® platform, our approach to studying protein motion with the goal of solving some of the toughest challenges in drug discovery. Relay was founded to make medicines for patients in need, and reaching an approval just 10 years later makes this a landmark validation for our R&D team's approach. Kudos and Yahzu to the dedicated Relayers who worked relentlessly to discover and develop this drug, congratulations to our partners at Elevar, and a sincere thank you to the patients, families, and investigators who have made this accomplishment possible.

There’s nothing quite like that moment when the team crowds around a desk to see promising experimental results. At Relay Tx, we're grateful for a research team that is committed to tackling some of the toughest targets in drug discovery. This is what it means to work on something that matters.

Today, we reported our second quarter financial results and corporate updates. Read more in our Q2 earnings release here. ir.relaytx.com/news-releases…

Today, we honor #CLOVES Awareness Day. Community changes what's possible in rare disease. It connects patients and families, informs research, and sustains the push for better care. We're proud to be working alongside @CLOVESSyndrome in this effort. Learn more about CLOVES at clovessyndrome.org.

Last weekend, we presented and connected with patients, families, and clinicians at the @KTSupportGroup's 40th Anniversary Conference at the Mayo Clinic. Our conversations at the conference reinforced the acute needs this patient community faces, reminding us of the impact we aim to have as we advance our vascular anomalies program. Thank you to the KT Support Group for 40 years of advocacy and for the community you've built. Insights from this weekend will continue to shape our work going forward.

This past weekend, members of the Relay Tx team volunteered at Betsy's Camp, an overnight camp for children with CLOVES syndrome and their families. Campers and families enjoyed a weekend of archery, ropes courses, arts and crafts, campfires, and meaningful time spent with others who share and understand their experiences. Moments like these are powerful reminders of our mission and the importance of fostering community, connection, and support for individuals and families navigating vascular anomalies. Thank you to the #CLOVESsyndrome community and Zebra Crossing for making it such a memorable weekend.

Relay Tx turned 10 years old and we took to the arcade, like a true 10 year old! A lot has changed in the past decade: ✔️Jean styles went from skinny to baggy ✔️Our Kendall Square neighborhood continued to grow as a leading biotech hub ✔️Ideas born in our labs are now being investigated in patients around the world

May is Lymphatic Malformation Awareness Month, a month dedicated to raising awareness and understanding of the two types of lymphatic malformations: isolated lymphatic malformations and complex lymphatic anomalies. At Relay Tx, we recognize the impact lymphatic malformations can have on individuals and families and remain committed to advancing research for the lymphatic malformations and broader vascular anomalies community. Learn more about lymphatic malformations and support available to the lymphatic malformation community from the patient advocacy group, @LGDAlliance: lgdalliance.org/

Today, we announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels, and surrounding tissues. The data, being presented this week at #ISSVA2026, demonstrated symptomatic improvement at 12 weeks in nearly all patients while maintaining a safety and tolerability profile showing potential for chronic use. These findings also support the potential advantage of PI3Kα mutant-selective inhibition. Click below for additional insights and more from President of R&D Don Bergstrom. ir.relaytx.com/news-releases…

Today, we reported first quarter 2026 financial results and highlighted continued progress across our pipeline. Details here. ir.relaytx.com/news-releases…

Today, we're pleased to announce new clinical data and plans to move zovegalisib + atirmociclib triplet combination into Phase 3 development in frontline patients with PI3Kα-mutated, HR+/HER2- metastatic #breastcancer. We aim to initiate this study early next year. Join us this morning, April 27, at 8:30am ET for our conference call to learn more. ir.relaytx.com/news-releases…

In continued recognition of International Children’s Book Day, Relay Tx acknowledges that children’s books can help communicate feelings and experiences related to rare diseases that are often hard to explain. For families living with vascular anomalies, everyday life can include navigating uncertainty, feelings of isolation, and comments about visible differences that can feel overwhelming, especially for children. By honestly explaining these unique journeys and experiences, children's books can help empower individuals and build understanding and acceptance. Today, we celebrate stories that shine a light on rare conditions and remind families that their experiences matter. They are not alone. Learn more about vascular anomalies children’s books and CLOVES Syndrome at lnkd.in/djrZQnh and FAVA at lnkd.in/eGvpDbji.

In the spirit of International Children’s Book Day last week, Relay Tx recognizes the power of children’s books to explain challenging topics in ways that are honest and compassionate. For families impacted by breast cancer, children's books can help open dialogue, normalize emotions, and remind families that they are not alone. These books can be a gentle way to support understanding, resilience, and connection during challenging moments. So today, we honor the authors, illustrators, patients, and families who use storytelling as a tool for comfort, courage, and care. Learn more about children’s books available for the breast cancer community: lbbc.org/about-breast-cancer…

New today: We’ve published a webinar focused on Vascular Anomalies education, intended to support broader understanding of the disease area, existing therapeutic options & ongoing clinical development of zovegalisib, our mutant-selective PI3Kα inhibitor. relaytx.com/pipeline

We were on the ground at #MBCC26 & were grateful for the opportunity to connect with investigators, research partners, & the #breastcancer community as we continue advancing innovative therapies for patients. Thanks to all who joined for our ReDiscover and ReDiscover-2 posters.

We were pleased to host BOD member Linda Hill & her coauthor Emily Tedards, as part of a tour for their new book “Genius at Scale.” They shared insights on building innovative companies by creating trust, encouraging bold ideas & fostering collaboration. Thank you Linda & Emily!

Today, we are pleased to report fourth quarter and full year 2025 financial results along with anticipated 2026 milestones. Listen below as CEO @SanjivKPatel1 shares more about the year ahead. Full details here. ir.relaytx.com/news-releases…

Ahead of #RareDiseaseDay, we gathered to better understand rare diseases & experiences of those living with them. As we advance our research in vascular anomalies & Fabry disease, we are today reminded of the unmet need in rare diseases & reinforce our commitment to patients.